Last 7 days
11.6%
Last 30 days
-12.7%
Last 90 days
-40%
Trailing 12 Months
-78.2%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 71.2M | 70.8M | 71.1M | 0 |
2022 | 9.3M | 11.7M | 17.5M | 27.1M |
2021 | 3.6M | 6.2M | 6.2M | 6.1M |
2020 | 1.7M | 2.2M | 3.2M | 4.0M |
2019 | 44.9M | 30.3M | 15.7M | 1.1M |
2018 | 43.2M | 48.7M | 62.3M | 59.5M |
2017 | 14.1M | 17.3M | 42.1M | 37.8M |
2016 | 14.7M | 12.2M | 9.7M | 14.2M |
2015 | 7.6M | 9.9M | 12.2M | 14.5M |
2014 | 0 | 825.0K | 3.1M | 5.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 01, 2023 | rawcliffe adrian | sold | -1,874 | 0.78 | -2,403 | chief executive officer |
Aug 01, 2023 | lunger john | sold | -2,803 | 0.9056 | -3,096 | chief patient supply officer |
Jul 10, 2023 | menzel garry e | sold | -43,447 | 0.9108 | -47,702 | - |
Jun 27, 2023 | rawcliffe adrian | sold | -2,146 | 0.92 | -2,333 | chief executive officer |
Jun 01, 2023 | menzel garry e | acquired | - | - | 209,931 | - |
Jun 01, 2023 | menzel garry e | acquired | - | - | 401,293 | - |
Jan 31, 2023 | piccina cintia | sold | -22,229 | 1.8696 | -11,890 | chief commercial officer |
Jan 17, 2023 | bertrand william c jr | sold | -8,249 | 1.858 | -4,440 | chief operating officer |
Jan 17, 2023 | rawcliffe adrian | sold | -18,685 | 1.858 | -10,057 | chief executive officer |
Jan 17, 2023 | lunger john | sold | -8,249 | 1.858 | -4,440 | chief patient supply officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Nov 15, 2023 | CAPTRUST FINANCIAL ADVISORS | unchanged | - | -3,179 | 17,101 | -% |
Nov 15, 2023 | GSA CAPITAL PARTNERS LLP | sold off | -100 | -32,000 | - | -% |
Nov 15, 2023 | Beaird Harris Wealth Management, LLC | unchanged | - | -14.00 | 72.00 | -% |
Nov 15, 2023 | MORGAN STANLEY | reduced | -1.24 | -321,335 | 1,600,050 | -% |
Nov 14, 2023 | Matrix Capital Management Company, LP | unchanged | - | -5,651,260 | 30,399,900 | 0.36% |
Nov 14, 2023 | TWO SIGMA INVESTMENTS, LP | reduced | -45.47 | -55,053 | 46,858 | -% |
Nov 14, 2023 | LAZARD ASSET MANAGEMENT LLC | added | 4.44 | - | 3,000 | -% |
Nov 14, 2023 | TANG CAPITAL MANAGEMENT LLC | added | 5.72 | -490,471 | 4,030,220 | 0.57% |
Nov 14, 2023 | MPM ASSET MANAGEMENT LLC | unchanged | - | -911,630 | 4,903,940 | 2.63% |
Nov 14, 2023 | CSS LLC/IL | unchanged | - | -13,151 | 70,748 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Nov 08, 2023 | long focus capital management, llc | 2.9% | 6,582,798 | SC 13G | |
Jul 10, 2023 | matrix capital management company, lp | 17.29% | 233,845,110 | SC 13G/A | |
Mar 30, 2023 | new enterprise associates 14, l.p. | 10.3% | 102,478,672 | SC 13D/A | |
Feb 14, 2023 | pfm health sciences, lp | 3.0% | 6 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 0.0% | 0 | SC 13G/A | |
Jan 18, 2023 | baillie gifford & co | 10.48% | 103,019,634 | SC 13G/A | |
Dec 02, 2022 | baillie gifford & co | 10.44% | 102,618,552 | SC 13G/A | |
May 09, 2022 | pfm health sciences, lp | 5.8% | 6 | SC 13G | |
Jan 18, 2022 | baillie gifford & co | 8.81% | 82,538,112 | SC 13G/A | |
Feb 16, 2021 | baker bros. advisors lp | 6.4% | 58,985,262 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Nov 14, 2023 | 8-K | Current Report | |
Nov 08, 2023 | SC 13G | Major Ownership Report | |
Nov 08, 2023 | 8-K | Current Report | |
Nov 08, 2023 | 10-Q | Quarterly Report | |
Nov 03, 2023 | 8-K | Current Report | |
Nov 01, 2023 | 3 | Insider Trading | |
Oct 31, 2023 | 8-K | Current Report | |
Sep 01, 2023 | 4 | Insider Trading | |
Aug 31, 2023 | 8-K | Current Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HILS | 32.8B | - | 14.55% | 467931.97% | -3.8K | 218.4K | - | -102.45% |
MRNA | 29.6B | 10.7B | 8.07% | -55.95% | -8.54 | 2.78 | -53.67% | -129.46% |
ALNY | 20.0B | 1.7B | 4.90% | -25.16% | -39.17 | 11.59 | 79.37% | 56.87% |
BMRN | 16.7B | 2.3B | 9.83% | -8.58% | 113.5 | 7.22 | 15.05% | 75.21% |
INCY | 11.8B | 3.6B | 0.63% | -32.44% | 27.88 | 3.28 | 8.35% | -51.49% |
MID-CAP | ||||||||
APLS | 5.7B | 272.9M | 1.64% | -5.18% | -9.43 | 20.95 | 141.38% | 4.43% |
BBIO | 5.2B | - | 21.89% | 247.20% | -8.88 | 48.33 | 54.84% | -12.96% |
ACAD | 3.6B | 631.9M | 1.65% | 46.39% | -24.37 | 5.74 | 23.54% | 31.53% |
AXSM | 3.1B | 223.4M | 6.77% | 16.65% | -15.53 | 14.03 | - | -26.24% |
ARWR | 3.1B | 256.2M | 21.69% | -2.64% | -16.98 | 12 | 2.51% | -17.66% |
SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 17.40% | -16.91% | 24.23 | 4.31 | 81.69% | -7.29% |
NVAX | 648.3M | 1.0B | -14.02% | -66.99% | -1.18 | 0.62 | -43.15% | 58.48% |
INO | 108.4M | 6.4M | 10.81% | -79.60% | -0.66 | 16.83 | -44.11% | 50.48% |
CRBP | 18.7M | - | -19.00% | 3569.57% | -0.39 | - | - | -13.74% |
IBIO | 8.0M | - | - | -82.21% | -0.12 | - | - | -29.23% |
Income Statement (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | 42.7% | 7,319,000 | 5,130,000 | 47,601,000 | 11,028,000 | 7,007,000 | 5,538,000 | 3,575,000 | 1,417,000 | 1,203,000 | 3,095,000 | 434,000 | 1,502,000 | 1,193,000 | 502,000 | 761,000 | 728,000 | 237,000 | 651,000 | 1,065,000 | 1,479,000 | 40,792,000 |
Costs and Expenses | 7.8% | 53,952,000 | 50,038,000 | 45,945,000 | 38,270,000 | 49,997,000 | 49,290,000 | 53,556,000 | 44,281,000 | 43,384,000 | 42,407,000 | 38,323,000 | 39,015,000 | 37,068,000 | 30,755,000 | 30,525,000 | 31,083,000 | 40,358,000 | 35,659,000 | 33,792,000 | 33,415,000 | 33,774,000 |
S&GA Expenses | -19.5% | 16,164,000 | 20,073,000 | 20,397,000 | 15,218,000 | 16,815,000 | 14,550,000 | 16,804,000 | 14,776,000 | 15,173,000 | 13,539,000 | 13,817,000 | 13,238,000 | 13,001,000 | 10,295,000 | 9,261,000 | 10,729,000 | 10,741,000 | 10,148,000 | 11,773,000 | 10,816,000 | 10,290,000 |
R&D Expenses | 26.1% | 37,788,000 | 29,965,000 | 25,548,000 | 23,052,000 | 33,182,000 | 34,740,000 | 36,752,000 | 29,505,000 | 28,211,000 | 28,868,000 | 24,506,000 | 25,777,000 | 24,067,000 | 20,460,000 | 21,264,000 | 20,354,000 | 29,617,000 | 25,511,000 | 22,019,000 | 22,599,000 | 23,484,000 |
EBITDA Margin | 100.0% | - | -1.16 | -1.49 | -5.81 | -9.58 | -14.41 | -17.64 | -24.67 | -23.97 | -22.90 | -38.36 | -32.83 | -38.52 | -56.75 | -82.16 | -122 | - | - | - | - | - |
Income Taxes | 1.0% | 687,000 | 680,000 | 625,000 | 994,000 | 399,000 | 470,000 | 634,000 | 209,000 | 208,000 | 76,000 | 298,000 | 52,000 | 15,000 | 25,000 | 70,000 | 88,000 | 87,000 | 65,000 | 2,000 | 135,000 | 133,000 |
Earnings Before Taxes | -116.9% | -44,914,000 | -20,709,000 | 1,661,000 | -28,256,000 | -41,022,000 | -44,050,000 | -49,631,000 | -38,649,000 | -42,193,000 | -38,992,000 | -37,465,000 | -36,561,000 | -35,417,000 | -29,855,000 | -28,097,000 | -29,276,000 | -39,215,000 | -41,022,000 | -27,410,000 | -35,868,000 | 5,375,000 |
EBT Margin | 100.0% | - | -1.25 | -1.57 | -6.00 | -9.88 | -14.87 | -18.24 | -25.58 | -24.90 | -23.85 | -38.36 | -32.83 | -38.52 | -56.75 | -82.16 | -122 | - | - | - | - | - |
Net Income | -113.2% | -45,601,000 | -21,389,000 | 1,036,000 | -29,250,000 | -41,421,000 | -44,520,000 | -50,265,000 | -38,858,000 | -42,401,000 | -39,068,000 | -37,763,000 | -36,613,000 | -35,432,000 | -29,880,000 | -28,167,000 | -29,364,000 | -39,302,000 | -41,087,000 | -27,412,000 | -36,173,000 | 5,242,000 |
Net Income Margin | 100.0% | - | -1.29 | -1.60 | -6.09 | -9.98 | -15.00 | -18.36 | -25.71 | -25.00 | -23.92 | -38.47 | -32.87 | -38.58 | -56.87 | -82.34 | -122 | - | - | - | - | - |
Free Cashflow | 100.0% | - | -44,978,000 | -39,632,000 | -1,373,000 | -58,166,000 | -50,211,000 | -61,515,000 | 129,912,000 | -46,834,000 | -33,231,000 | -47,692,000 | -30,383,000 | -17,031,000 | -25,183,000 | 16,665,000 | -12,688,000 | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | -13.5% | 297 | 343 | 288 | 329 | 332 | 388 | 420 | 470 | 354 | 390 | 412 | 451 | 479 | 512 | 285 | 182 | 208 | 240 | 270 | 277 | 310 |
Current Assets | -16.2% | 219 | 262 | 214 | 255 | 264 | 321 | 359 | 415 | 300 | 337 | 359 | 398 | 427 | 458 | 228 | 120 | 147 | 175 | 200 | 231 | 262 |
Cash Equivalents | 20.9% | 93.00 | 77.00 | 120 | 108 | 79.00 | 100 | 91.00 | 152 | 45.00 | 55.00 | 37.00 | 61.00 | 83.00 | 127 | 91.00 | 55.00 | 44.00 | 39.00 | 54.00 | 72.00 | 157 |
Net PPE | -5.3% | 53.00 | 55.00 | 54.00 | 54.00 | 48.00 | 45.00 | 37.00 | 30.00 | 29.00 | 29.00 | 28.00 | 28.00 | 27.00 | 27.00 | 29.00 | 31.00 | 32.00 | 34.00 | 36.00 | 36.00 | 38.00 |
Liabilities | -3.6% | 209 | 216 | 204 | 247 | 219 | 246 | 257 | 264 | 113 | 112 | 102 | 110 | 103 | 105 | 99.00 | 58.00 | 61.00 | 53.00 | 51.00 | 30.00 | 33.00 |
Current Liabilities | -1.3% | 75.00 | 76.00 | 64.00 | 65.00 | 66.00 | 74.00 | 66.00 | 63.00 | 41.00 | 41.00 | 31.00 | 39.00 | 35.00 | 39.00 | 30.00 | 34.00 | 37.00 | 28.00 | 23.00 | 24.00 | 30.00 |
Shareholder's Equity | -30.4% | 88.00 | 127 | 84.00 | 82.00 | 113 | 142 | 163 | 206 | 241 | 278 | 309 | 341 | 376 | 408 | 186 | 124 | 148 | 187 | 220 | 247 | 276 |
Retained Earnings | -4.9% | -975 | -929 | -908 | -909 | -880 | -838 | -794 | -743 | -704 | -662 | -623 | -585 | -549 | -513 | -483 | -455 | -426 | -387 | -345 | -318 | -282 |
Additional Paid-In Capital | 0.4% | 1,061 | 1,058 | 993 | 991 | 985 | 980 | 965 | 960 | 955 | 950 | 942 | 936 | 933 | 929 | 678 | 586 | 583 | 581 | 578 | 574 | 570 |
Accumulated Depreciation | 4.7% | 43.00 | 41.00 | 39.00 | 39.00 | 35.00 | 36.00 | 37.00 | 36.00 | 35.00 | 34.00 | 33.00 | 31.00 | 29.00 | 26.00 | 24.00 | 24.00 | 21.00 | 20.00 | 18.00 | 16.00 | - |
Shares Outstanding | 0.7% | 1,362 | 1,352 | 994 | 987 | 983 | 963 | 940 | 929 | 937 | 934 | 931 | 929 | 928 | 781 | 740 | 631 | 629 | 629 | 628 | 584 | 582 |
Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | -3.2% | -45,159 | -43,762 | -37,283 | 2,042 | -48,159 | -41,251 | -54,401 | 133,928 | -45,200 | -31,459 | -46,540 | -29,216 | -16,317 | -24,915 | 16,857 | -12,528 | -29,608 | -34,168 | -36,203 | -31,685 | 9,939 |
Share Based Compensation | -17.1% | 3,179 | 3,837 | 1,676 | 3,946 | 3,663 | 5,045 | 5,586 | 4,827 | 5,019 | 5,449 | 5,334 | 3,062 | 3,280 | 2,624 | 1,448 | 2,558 | 1,820 | 3,196 | 3,479 | 3,749 | 4,042 |
Cashflow From Investing | 2027.2% | 57,306 | 2,694 | 48,341 | 20,952 | 28,851 | 44,109 | -4,775 | -28,491 | 34,851 | 47,678 | 21,762 | 7,608 | -27,580 | -187,005 | -71,947 | 23,683 | 35,045 | 18,561 | 17,656 | -52,411 | 942 |
Cashflow From Financing | 4157.1% | 596 | 14.00 | 196 | 1,403 | 1,452 | 9,977 | 35.00 | 52.00 | 139 | 2,563 | 534 | 122 | 466 | 248,019 | 91,444 | - | - | 330 | 36.00 | 104 | 100,162 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||
Revenue | $ 7,319,000 | $ 7,007,000 | $ 60,050,000 | $ 16,120,000 |
Operating expenses | ||||
Research and development | (37,788,000) | (33,182,000) | (93,301,000) | (104,674,000) |
General and administrative | (16,164,000) | (16,815,000) | (56,634,000) | (48,169,000) |
Total operating expenses | (53,952,000) | (49,997,000) | (149,935,000) | (152,843,000) |
Operating loss | (46,633,000) | (42,990,000) | (89,885,000) | (136,723,000) |
Interest income | 2,149,000 | 324,000 | 4,368,000 | 1,019,000 |
Gain on bargain purchase | 22,049,000 | |||
Remeasurement on bargain purchase | (106,000) | |||
Other income (expense), net | (324,000) | 1,644,000 | (494,000) | 1,001,000 |
Loss before income tax expense | (44,914,000) | (41,022,000) | (63,962,000) | (134,703,000) |
Income tax expense | (687,000) | (399,000) | (1,992,000) | (1,503,000) |
Net loss attributable to ordinary shareholders | $ (45,601,000) | $ (41,421,000) | $ (65,954,000) | $ (136,206,000) |
Net loss per ordinary share | ||||
Basic (in dollars per share) | $ (0.03) | $ (0.04) | $ (0.06) | $ (0.14) |
Diluted (in dollars per share) | $ (0.03) | $ (0.04) | $ (0.06) | $ (0.14) |
Weighted average shares outstanding: | ||||
Basic (in shares) | 1,357,849,656 | 980,791,114 | 1,153,791,567 | 961,354,122 |
Diluted (in shares) | 1,357,849,656 | 980,791,114 | 1,153,791,567 | 961,354,122 |
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 90,059,000 | $ 108,033,000 |
Marketable securities - available-for-sale debt securities | 71,669,000 | 96,572,000 |
Accounts receivable, net of allowance for expected credit losses of $0 and $0 | 789,000 | 7,435,000 |
Other current assets and prepaid expenses | 56,851,000 | 43,330,000 |
Total current assets | 219,368,000 | 255,370,000 |
Restricted cash | 3,013,000 | 1,569,000 |
Operating lease right-of-use assets, net of accumulated amortization of $11,930 and $9,470 | 21,302,000 | 18,019,000 |
Property, plant and equipment, net of accumulated depreciation of $42,543 and $38,588 | 52,571,000 | 53,516,000 |
Intangible assets, net of accumulated amortization of $5,008 and $4,676 | 384,000 | 442,000 |
Total assets | 296,638,000 | 328,916,000 |
Current liabilities | ||
Accounts payable | 13,922,000 | 4,753,000 |
Operating lease liabilities, current | 5,081,000 | 2,728,000 |
Accrued expenses and other current liabilities | 26,831,000 | 31,215,000 |
Restructuring provision | 2,285,000 | |
Deferred revenue, current | 29,312,000 | 23,520,000 |
Total current liabilities | 75,146,000 | 64,501,000 |
Operating lease liabilities, non-current | 20,520,000 | 20,349,000 |
Deferred revenue, non-current | 111,487,000 | 160,892,000 |
Other liabilities, non-current | 1,356,000 | 1,296,000 |
Total liabilities | 208,509,000 | 247,038,000 |
Stockholders' equity | ||
Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,361,595,036 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding) | 1,863,000 | 1,399,000 |
Additional paid in capital | 1,061,420,000 | 990,656,000 |
Accumulated other comprehensive gain/(loss) | 102,000 | (875,000) |
Accumulated deficit | (975,256,000) | (909,302,000) |
Total stockholders' equity | 88,129,000 | 81,878,000 |
Total liabilities and stockholders' equity | $ 296,638,000 | $ 328,916,000 |
 CEO | Mr. Adrian G. Rawcliffe |
---|---|
 WEBSITE | www.adaptimmune.com |
 EMPLOYEES | 534 |